{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:29:07Z","timestamp":1793795347493,"version":"4.6.1"},"reference-count":29,"publisher":"American Chemical Society (ACS)","issue":"15","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/na","name":"International Consortium for Innovation and Quality in Pharmaceutical Development","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Concerns about long-chain per- and polyfluoroalkyl substances (PFAS), e.g. PFOS, PFOA, PFNA, have led to broad regulatory initiatives that often treat PFAS as a single class, unintentionally encompassing carbon\u2013fluorine motifs essential to medicinal chemistry. This Perspective examines the implications for small-molecule drug discovery, focusing on \u2212CF2\u2013 and \u2212CF3 groups used in active pharmaceutical ingredients. Survey data from medicinal chemistry departments across multiple pharmaceutical organizations highlight the routine use of fluorinated substituents to optimize target engagement, selectivity, permeability, metabolic stability, and systemic exposure, particularly in demanding therapeutic areas. Examples from recently approved drugs and the WHO Model List of Essential Medicines demonstrate how these motifs enable translation of challenging targets into effective therapies. We further discuss the risks of generalized PFAS classifications for pharmaceuticals and emphasize the need for context-specific regulatory approaches that preserve innovation while addressing environmental concerns.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01042","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:11:35Z","timestamp":1785849095000},"page":"17663-17675","source":"Crossref","is-referenced-by-count":1,"title":["Medicinal Chemistry\nPerspectives on PFAS in Drug Design:\nFluorinated Motifs, Innovation, and Patient Impact"],"prefix":"10.1021","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9623-1406","authenticated-orcid":true,"given":"Leena A.","family":"Otsomaa","sequence":"first","affiliation":[{"name":"Orion Corporation , , Orionintie 1 , ,","place":["Espoo, Finland, 02200"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1226-1868","authenticated-orcid":true,"given":"Michelle R.","family":"Garnsey","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8020-4828","authenticated-orcid":true,"given":"Harrie J. M.","family":"Gijsen","sequence":"additional","affiliation":[{"name":"Johnson &Johnson Innovative Medicine , , ,","place":["Beerse, Belgium, B-2340"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6289-8341","authenticated-orcid":true,"given":"Peter T. W.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb R & D , , P.O. Box 4000, , ,","place":["Princeton, New Jersey, United States, 08540"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , , , ,","place":["Foster City, California, United States, 94404"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Menon","sequence":"additional","affiliation":[{"name":"Veterinary Medicine Research and Development, Zoetis , , 333 Portage Street , , ,","place":["Kalamazoo, Michigan, United States, 49007"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Ott","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals , , , ,","place":["West Chester, Pennsylvania, United States, 19380"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafydd R.","family":"Owen","sequence":"additional","affiliation":[{"name":"Pfizer Research and Development , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026081311100512000_cit1","first-page":"23","volume-title":"Reconciling\nTerminology of the Universe of Per- and Polyfluoroalkyl Substances\nOECD Series on Risk Management of Chemicals","year":"2021"},{"issue":"11","key":"2026081311100512000_cit2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/d41573-021-00190-9","article-title":"Clinical development\ntimes for innovative drugs","volume":"21","author":"Brown","year":"2022","journal-title":"Nat. Rev. Drug Discov"},{"issue":"8","key":"2026081311100512000_cit3","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3390\/microorganisms10081664","article-title":"Strategies\nfor the Biodegradation of Polyfluorinated Compounds","volume":"10","author":"Wackett","year":"2022","journal-title":"Microorganisms"},{"key":"2026081311100512000_cit4","doi-asserted-by":"crossref","DOI":"10.1021\/acs.oprd.6c00114","article-title":"The Synthetic Role of PFAS\nin Drug Substance Manufacturing:\nAn IQ Consortium Working Group Review on the Potential Impact of PFAS\nRestrictions on Patient Access to Medicines","author":"Scotney","year":"2026"},{"issue":"21","key":"2026081311100512000_cit5","doi-asserted-by":"publisher","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications\nof Fluorine in Medicinal Chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med.\nChem."},{"key":"2026081311100512000_cit6","doi-asserted-by":"publisher","first-page":"108311","DOI":"10.1016\/j.envint.2023.108311","article-title":"Target\nand non-target analyses of neutral per- and polyfluoroalkyl substances\nfrom fluorochemical industries using GC-MS\/MS and GC-TOF: Insights\non their environmental fate","volume":"182","author":"Mok","year":"2023","journal-title":"Environ. Int."},{"key":"2026081311100512000_cit7","doi-asserted-by":"publisher","first-page":"123792","DOI":"10.1016\/j.carbpol.2025.123792","article-title":"Breaking free from PFAS:\nbiocompatible, durable and\nhigh-performance octenyl succinic anhydride (OSA)-modified starch\/chitosan\ncoating with ZnO for textile applications","volume":"365","author":"Verbic","year":"2025","journal-title":"Carbohydr.\nPolym."},{"key":"2026081311100512000_cit8","unstructured":"Cortellis Competitive Intelligence.\n          . Cortellis\nCompetitive Intelligence. www.clarivate.com (Accessed\nOct. 13, 2025)."},{"issue":"1","key":"2026081311100512000_cit9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small\nmolecules in targeted cancer therapy: advances, challenges,\nand future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target\nTher"},{"issue":"8","key":"2026081311100512000_cit10","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1038\/s41591-025-03834-0","article-title":"The Global Neurodegeneration Proteomics Consortium: biomarker and\ndrug target discovery for common neurodegenerative diseases and aging","volume":"31","author":"Imam","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"2026081311100512000_cit11","doi-asserted-by":"publisher","first-page":"104255","DOI":"10.1016\/j.drudis.2024.104255","article-title":"Neuropsychiatric\ndrug development: Perspectives on\nthe current landscape, opportunities and potential future directions","volume":"30","author":"Loiodice","year":"2025","journal-title":"Drug Discov Today"},{"issue":"13","key":"2026081311100512000_cit12","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.2174\/1381612826666200224112534","article-title":"Drug Development for Central Nervous System Diseases\nUsing In vitro Blood-brain Barrier Models and Drug Repositioning","volume":"26","author":"Morofuji","year":"2020","journal-title":"Curr. Pharm. Des."},{"issue":"12","key":"2026081311100512000_cit13","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1021\/ed1003806","article-title":"A Graphical\nJourney of Innovative\nOrganic Architectures That Have Improved Our Lives","volume":"87","author":"McGrath","year":"2010","journal-title":"J. Chem. Educ."},{"key":"2026081311100512000_cit14","unstructured":"Cortellis Drug Discovery Intelligence.\n          . Cortellis Drug Discovery Intelligence. www.clarivate.com (Accessed.Jan.\n5, 2026)."},{"issue":"20","key":"2026081311100512000_cit15","doi-asserted-by":"publisher","first-page":"21072","DOI":"10.1021\/acs.jmedchem.5c01625","article-title":"Discovery\nof Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor\nfor HIV-1 Treatment and Pre-exposure Prophylaxis","volume":"68","author":"Canales","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026081311100512000_cit16","unstructured":"eEML - Electronic Essential Medicines List. World Health Organization, https:\/\/list.essentialmeds.org\/(accessed."},{"issue":"5","key":"2026081311100512000_cit17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrc801","article-title":"A history of prostate\ncancer treatment","volume":"2","author":"Denmeade","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"2026081311100512000_cit18","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery\nof ODM-201, a new-generation\nandrogen receptor inhibitor targeting resistance mechanisms to androgen\nsignaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci. Rep"},{"issue":"20","key":"2026081311100512000_cit19","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1021\/acs.jmedchem.5b01101","article-title":"1,4-Oxazine\nbeta-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally\nBioavailable Brain Penetrant Leads","volume":"58","author":"Rombouts","year":"2015","journal-title":"J. Med.\nChem."},{"issue":"12","key":"2026081311100512000_cit20","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1021\/acs.jmedchem.8b00304","article-title":"Optimization of 1,4-Oxazine\nbeta-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate","volume":"61","author":"Gijsen","year":"2018","journal-title":"J. Med. Chem."},{"issue":"20","key":"2026081311100512000_cit21","doi-asserted-by":"publisher","first-page":"15262","DOI":"10.1021\/acs.jmedchem.1c01300","article-title":"Discovery\nof Umibecestat (CNP520): A Potent, Selective,\nand Efficacious beta-Secretase (BACE1) Inhibitor for the Prevention\nof Alzheimer\u2019s Disease","volume":"64","author":"Machauer","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3\u20134","key":"2026081311100512000_cit22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.vetpar.2014.02.020","article-title":"Discovery\nand mode of action of afoxolaner, a new isoxazoline\nparasiticide for dogs","volume":"201","author":"Shoop","year":"2014","journal-title":"Vet. Parasitol."},{"issue":"3","key":"2026081311100512000_cit23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/jpet.122.001449","article-title":"TAK-994, a Novel Orally\nAvailable Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses\nFragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse\nModels of Narcolepsy","volume":"385","author":"Ishikawa","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"2026081311100512000_cit24","doi-asserted-by":"publisher","first-page":"20838","DOI":"10.1038\/s41598-024-70594-1","article-title":"TAK-861, a\npotent, orally available orexin receptor\n2-selective agonist, produces wakefulness in monkeys and improves\nnarcolepsy-like phenotypes in mouse models","volume":"14","author":"Mitsukawa","year":"2024","journal-title":"Sci. Rep"},{"issue":"2","key":"2026081311100512000_cit25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/toxsci\/kfaf003","article-title":"TAK-994\nmechanistic investigation into drug-induced\nliver injury","volume":"204","author":"Shinozawa","year":"2025","journal-title":"Toxicol. Sci."},{"key":"2026081311100512000_cit26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/jamaneurol.2025.4825","article-title":"Effects of Oveporexton,\nan Orexin Receptor 2-Selective\nAgonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of\na Randomized Clinical Trial","volume":"83","author":"Lammers","year":"2026","journal-title":"JAMA Neurol"},{"issue":"3","key":"2026081311100512000_cit27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/0024-3205(74)90345-2","article-title":"A selective\ninhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine","volume":"15","author":"Wong","year":"1974","journal-title":"Life Sci."},{"issue":"5","key":"2026081311100512000_cit28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0024-3205(95)00209-O","article-title":"Prozac (fluoxetine,\nLilly 110140),\nthe first selective serotonin uptake inhibitor and an antidepressant\ndrug: twenty years since its first publication","volume":"57","author":"Wong","year":"1995","journal-title":"Life Sci."},{"key":"2026081311100512000_cit29","doi-asserted-by":"publisher","first-page":"Review","DOI":"10.1016\/j.scp.2026.102416","article-title":"Per- and polyfluorinated active pharmaceutical\ningredients:\nOverview and alternatives","volume":"52","author":"Greinke","year":"2026","journal-title":"Sustainable Chem.\nPharm."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01042","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/15\/17663\/66303514\/acs.jmedchem.6c01042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/15\/17663\/66303514\/acs.jmedchem.6c01042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:10:42Z","timestamp":1786633842000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/15\/17663\/5235256\/Medicinal-Chemistry-Perspectives-on-PFAS-in-Drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":29,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01042","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}